GENELUX Corp (GNLX) research

GENELUX Corp
ShareXLinkedInReddit
Sector
Healthcare
Industry
Biotechnology
Last price
$2.61
As of

GENELUX Corp (GNLX): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-13.

As of . Source: SEC EDGAR filings for GNLX. Method and limitations.

SHARE THIS CARD

Share the GNLX intelligence card

A branded snapshot of GNLX: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion GNLX intelligence card preview
Post to X
LIVE TERMINAL

See GNLX live in the terminal

Track GNLX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live GNLX terminal, free

Active signals for GNLX

FREE, NO ACCOUNT

Every signal on GNLX, as it fires

You are seeing 5 of 10 signals recorded on GNLX since 2026-05-31.

The five above landed across 2 days. The other 5 were recorded on 1 other days. 7 of the 10 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in GNLX (2026Q2)

Manager / securityMarket value% portfolioQoQ
RENAISSANCE TECHNOLOGIES LLCCUSIP 36870H103 · 2026Q2$317K0.00%,
CITADEL ADVISORS LLCCUSIP 36870H103 · 2026Q2$257K0.00%,
Point72 Asset Management, L.P.CUSIP 36870H103 · 2026Q2$71K0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, GNLX

GNLX against its peers

GNLX's operating margin of -415175.0% ranks in the 5th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.

MetricGNLXPeer medianPercentilen
Revenue FY8000 USD2.1M USD2712
Operating margin-415175.0%-477.5%59
Net margin-401812.5%-1679.5%510
Return on equity-278.5%-94.5%1720

Peers (23): MIST, VANI, VXRT, BDTX, VTVT, EQ, CBUS, KZIA, AARD, NAUT, BMEA, PMN, OKUR, MNOV, COYA, PYPD, LENZ, CRDF, SMNR, PLYX, UNCY, INO, NMRA. Left out: TLSA (period gap), CNXU (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (GNLX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more GNLX signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to GNLXand get the insider, 13F, options, and confluence read in one view.

Open the live GNLX terminal, free